Polaris Capital Management’s Top Stock Picks

Polaris Capital Management, founded in 1995, is an international value equity investment firm. It recently reported that it manages over $4 billion from a diversified client base. Polaris’s manager, Bernard Horn, formerly worked at MDT Advisers and holds a master’s degree in management from MIT’s Sloan School. Polaris likes to look at a company’s operating cash flow minus its maintenance capital expenditures in order to determine value. We have gone through the fund’s recent 13F filing, which disclosed some of its equity positions. Review our list of the fund’s stock positions or read more about its top five 13F holdings:

Polaris’s largest position, according to the 13F, was Teva Pharmaceutical Industries Ltd (NYSE:TEVA). The fund owned 1.6 million shares of the $35 billion market cap provider of generic and branded pharmaceutical products. Teva offers an intriguing mix of value and growth. In its most recent quarter, revenue increased 19% and earnings increased 50% compared to the same quarter in 2011. Yet the company is actually cheap on a historical basis at 11 times trailing earnings. The sell-side expects some degree of growth to continue, yielding a forward P/E of only 7. The stock also pays a moderate dividend yield of 2.1% and, as a pharmaceutical company, has a beta of only 0.7. We might look at it a bit more in the future.

Andreas Halvorsen

$3.3 billion market cap baby and children’s apparel company Carter’s, Inc. (NYSE:CRI) was another of the fund’s favorite stocks, as it owned 1.1 million shares at the end of June. Carter’s, which owns the OshKosh brand, has seen its stock rise 88% over the last year and it reported strong growth last quarter (revenue was 20% higher, and earnings were 64% higher, than the same period last year). The rise in the stock price has left Carter’s with quite a bit of future growth priced in, at trailing and forward P/E multiples of 27 and 17, respectively. Andreas Halvorsen’s Viking Global was a major shareholder at the end of the second quarter.

Polaris reported a position of 1.2 million shares in Infosys Ltd (NASDAQ:INFY), which offers strategy and technology consulting services to business customers. Infosys, which is experiencing moderate growth, has trailing and forward P/E multiples in the teens as the market does not expect much growth at the company in the future. Infosys is down 10% so far this year despite a rising market, and is widely shorted with a short ratio of 16 as of the most recent data.

Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) is a $1.8 billion market cap biotech company whose primary product, H.P. Acthar Gel, acts as a treatment for multiple sclerosis. Polaris owned about 910,000 shares of the stock at the end of June, unchanged from the beginning of the quarter. Questcor has something of a hidden gem factor going for it: its revenue and earnings last quarter were more than double what they were in the same period in the previous year. The growth is expected to continue, as the stock trades at 14 times trailing earnings, 7 times forward estimates, and a five-year PEG ratio of 0.5. We think investors might want to look more closely at this stock. Healthcare guru Samuel Isaly has a large stake in this biotech company as well.

Finally, the fund’s 13F filing showed a substantial stake (about 690,000 shares) in NextEra Energy, Inc. (NYSE:NEE). Nextera, an electric utility with a strong position in renewable energy to complement its more traditionally fueled power plants, was formerly known as FPL. Billionaire Israel Englander’s Millennium Management more than doubled its own position during the second quarter, and closed June with about 750,000 shares of the company. Nextera, which pays a 3.6% dividend yield, trades at a trailing P/E of 13 and a forward P/E of 14.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!